Does OptumRx Cover Weight-Loss Drugs? (2026)

Short version: OptumRx is a pharmacy benefit manager (PBM) owned by UnitedHealth Group through its Optum division — it is not an insurance company. OptumRx publishes the formulary, sets the drug tiers, and runs prior authorization for the plans it administers (including most UnitedHealthcare commercial plans and many other employer and health-plan clients). For type 2 diabetes, GLP-1s like Ozempic, Mounjaro, Trulicity, and Rybelsus sit on the OptumRx commercial formulary with prior authorization. For chronic weight management, OptumRx places Wegovy and Zepbound on Tier 2 with prior authorization and quantity limits — but only on plans whose plan sponsor (the employer or health plan) chose to cover anti-obesity medications. That plan-sponsor decision, not OptumRx's clinical policy, is the thing that most often determines whether you can get a weight-loss GLP-1.

At a glance

• What OptumRx is: a pharmacy benefit manager owned by UnitedHealth Group (Optum). It administers prescription benefits — formulary, tiers, prior authorization, mail-order — for UnitedHealthcare commercial plans and many external employer and health-plan clients. It is not itself an insurer.^[1]
• GLP-1s for type 2 diabetes: generally covered. Ozempic, Mounjaro, Trulicity, and Rybelsus appear on the OptumRx commercial formulary (typically Tier 2) with prior authorization and quantity limits.^[2]
• GLP-1s for chronic weight management: CONDITIONAL. Wegovy and Zepbound are placed on Tier 2 with prior authorization and quantity limits — but coverage applies only on plans whose plan sponsor included anti-obesity medications in the benefit.^[3][4]
• The plan-sponsor reality: whether weight-loss drugs are covered is an employer/health-plan decision, not an OptumRx-wide one. Many plan sponsors exclude AOMs to control cost; OptumRx surveys show employers are broadly accepting of GLP-1 use but unprepared for the cost surge.^[5]
• OptumRx kept Zepbound on formulary for 2026: unlike CVS Caremark, which removed Zepbound from most commercial formularies effective July 1, 2025 in favor of Wegovy as its preferred obesity GLP-1, OptumRx maintained Zepbound on its 2026 formularies for plans that cover obesity medications.^[4][6]
• Wegovy cardiovascular indication: as of January 2025, OptumRx added Wegovy to its Premium Formulary for the FDA-approved indication of reducing major adverse cardiovascular events in adults with established CVD plus overweight/obesity — coverable even on plans that do not cover Wegovy for weight loss.^[3][7]
• Prior authorization + BMI + step therapy: weight-management PA criteria typically require BMI ≥30, or ≥27 with a weight-related comorbidity, plus a documented lifestyle program; the exact step-therapy rules are plan-specific.^[8]
• Medicare Part D (administered by OptumRx for many plans): NO coverage of GLP-1s for weight loss alone under the federal Part D exclusion; YES for diabetes GLP-1s and for Wegovy's cardiovascular indication.^[9]

OptumRx is a PBM, not an insurer — why that changes the question

The most common point of confusion is treating OptumRx like an insurance company. It is not. OptumRx is a pharmacy benefit manager (PBM) — a third-party administrator of the prescription-drug portion of a health plan. It is one of the three largest PBMs in the United States (alongside CVS Caremark and Express Scripts), and it is owned by UnitedHealth Group through its Optum health-services arm.^[1]

As a PBM, OptumRx does several jobs on behalf of its clients:

• Publishes the formulary — the list of covered drugs and the tier each one sits on (e.g., the Premium Standard and Select Standard commercial formularies).^[2]
• Negotiates with manufacturers for rebates and net pricing. OptumRx has stated that rebate agreements bring the net cost of GLP-1s for payers down to roughly $700/month, even though list prices are far higher.^[5]
• Runs prior authorization and utilization management — the BMI, comorbidity, step-therapy, and quantity-limit rules attached to a drug.^[8]
• Operates mail-order and specialty pharmacy and adjudicates claims at retail pharmacies.

But OptumRx does not unilaterally decide who gets weight-loss drugs. Its clients — the plan sponsors, meaning the employers and health plans that hire OptumRx — choose the benefit design, including the single most important lever for obesity drugs: whether anti-obesity medications (AOMs) are a covered benefit at all. OptumRx offers a standard formulary and add-on programs, but the plan sponsor selects what to buy. This is why two people with identical BMIs and identical OptumRx cards can get completely different answers about Wegovy: their employers made different benefit choices.

OptumRx is the PBM behind most UnitedHealthcare commercial plans, so the structure mirrors what we describe in our UnitedHealthcare coverage review — but OptumRx also administers benefits for many employers and health plans that are not UnitedHealthcare-insured at all.

GLP-1 coverage for type 2 diabetes (broadly covered)

On the OptumRx commercial formulary, GLP-1 receptor agonists for the type 2 diabetes indication are broadly on-formulary with prior authorization and quantity limits. The agents commonly covered:

• Ozempic (semaglutide) — once-weekly injection; typically Tier 2 with PA and quantity limit. FDA-approved for T2D plus CV risk reduction in T2D with established CVD.^[2]
• Mounjaro (tirzepatide) — once-weekly dual GIP/GLP-1; typically Tier 2 with PA and quantity limit. FDA-approved for T2D. See our Aetna coverage review for how a different payer treats the same drugs.
• Trulicity (dulaglutide) — once-weekly GLP-1; typically Tier 2 with PA. FDA-approved for T2D plus CV risk reduction.
• Rybelsus (oral semaglutide) — daily oral tablet; typically Tier 2 with PA. FDA-approved for T2D.

Typical OptumRx PA criteria for a T2D GLP-1: a confirmed type 2 diabetes diagnosis, a documented A1C, usually a trial of metformin (or documented intolerance/contraindication), and prescriber documentation of treatment goals. Because the diabetes indication is not a weight-loss indication, these drugs are generally covered regardless of whether the plan sponsor bought an anti-obesity-medication benefit.

GLP-1 coverage for chronic weight management (depends on the plan sponsor's AOM decision)

This is where OptumRx coverage becomes conditional. The FDA-approved anti-obesity GLP-1s — Wegovy (semaglutide 2.4 mg), Zepbound (tirzepatide), and Saxenda (liraglutide 3.0 mg) — are placed on the OptumRx commercial formulary at Tier 2 with prior authorization and quantity limits, with special-pharmacy handling on some designs.^[3][4] But that formulary placement only takes effect on plans whose plan sponsor included anti-obesity medications in the pharmacy benefit. On plans that excluded AOMs, these drugs are not covered for weight loss at all.

One important contrast with OptumRx's largest competitor: CVS Caremark removed Zepbound from most of its commercial template formularies effective July 1, 2025, selecting Wegovy as its preferred obesity GLP-1. OptumRx did not follow that move — it maintained Zepbound on its 2026 formularies for plans that cover obesity medications, so OptumRx members on AOM-covered plans generally retain access to both Wegovy and Zepbound.^[4][6] This is a meaningful practical difference if you specifically need or prefer tirzepatide.

When AOMs are a covered benefit, the broad OptumRx commercial PA criteria for a weight-management GLP-1 are:

• BMI ≥30 kg/m², OR BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, established cardiovascular disease, or — for Zepbound — moderate-to-severe obstructive sleep apnea).^[8]
• Age 18 or older (Wegovy also carries a pediatric 12+ indication).
• Documentation of a comprehensive lifestyle intervention — diet and physical-activity counseling. Some plan designs specify a trial period within a recent window; the exact duration is plan-specific.^[8]
• A time-limited authorization, after which continuation requires documented clinically meaningful weight loss.^[8]

OptumRx also markets a wraparound program called Weight Engage, launched in December 2023 — a plan-sponsor-configurable obesity-management solution that pairs GLP-1 coverage with provider networks, coaching, and lifestyle support to manage cost and outcomes.^[5] Whether your plan layers Weight Engage (or a stricter utilization-management package) on top of the formulary is, again, a plan-sponsor decision.

The Wegovy cardiovascular indication — covered even when weight loss isn't

A consequential 2025 change: after the FDA approved Wegovy to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease plus overweight or obesity, OptumRx added Wegovy to its Premium Formulary for that cardiovascular indication as of January 2025 — requiring even plans that do not cover Wegovy for weight loss to cover it for CV risk reduction.^[3][7]

Benefit exclusion vs PA denial — they are not the same thing

This distinction determines what you can do about a “no.”

• A PA denial means the drug class IS covered by your plan but you have not met or documented the clinical criteria. This is appealable — resubmit with the missing BMI, comorbidity, or lifestyle-program documentation, then escalate.
• A benefit exclusion means your plan sponsor did not buy AOM coverage, so weight-loss drugs are not part of your pharmacy benefit at all. A clinical appeal will not reverse this, because there is no clinical question — it is a contract term. The realistic levers are: ask HR/benefits whether an AOM rider can be added at renewal, pursue a covered non-weight-loss indication (cardiovascular risk, OSA), or use a cash-pay pathway.

Confirm which one you are facing before spending effort on an appeal. Your plan's Summary Plan Description (SPD) or Evidence of Coverage (EOC) lists AOM exclusions explicitly in the excluded-benefits section.

Medicare Part D administered by OptumRx — federal weight-loss exclusion

OptumRx administers prescription benefits for many Medicare Part D and Medicare Advantage prescription-drug plans. Like every Part D plan, these operate under Social Security Act §1860D-2(e)(2)(A), which excludes “agents when used for the symptomatic relief of cough and colds, anorexia, weight loss, or weight gain” from Part D coverage.^[9] This is a federal statutory exclusion — an OptumRx-administered Medicare plan cannot cover Wegovy, Zepbound, or Saxenda for weight-loss-only indications, regardless of medical necessity.

Three exceptions where an OptumRx-administered Medicare plan CAN cover otherwise-excluded GLP-1s:

• Ozempic / Mounjaro / Trulicity for type 2 diabetes. T2D is not a weight-loss indication, so the §1860D-2(e)(2)(A) exclusion does not apply.^[9]
• Wegovy for cardiovascular risk reduction. Wegovy's CV indication is a distinct non-weight-loss indication and is coverable on Medicare Part D; CMS confirmed in 2024 that Part D plans may cover semaglutide for the CV-risk indication.^[7][9]
• Zepbound for moderate-to-severe obstructive sleep apnea. The FDA approved this distinct indication on December 20, 2024; because OSA is not weight loss, the Part D exclusion does not block it.^[10]

How to find out if YOUR OptumRx plan covers Wegovy or Zepbound

Four reliable ways, in order from fastest to most authoritative:

1. optumrx.com member portal → Pharmacy / Prescription Drug List. Sign in, select your plan, and search for “Wegovy” or “Zepbound.” The result indicates the tier and whether prior authorization is required. This is the canonical source for your specific plan's formulary.^[2]
2. Ask HR or your benefits administrator the AOM question directly. Because weight-loss-drug coverage is a plan-sponsor decision, the fastest definitive answer is often: “Does our pharmacy benefit include anti-obesity medications?” If the answer is no, no PA will succeed.
3. Phone the OptumRx member number on your card. Ask specifically: “Is (drug name) a covered benefit on my plan for chronic weight management? What is the copay tier and the PA requirement, and is there a step-therapy rule?”
4. Request the Summary Plan Description (SPD) or Evidence of Coverage (EOC). The SPD/EOC is the legal contract describing exactly what is covered. AOM exclusions, if present, are listed in the excluded-benefits section.

Prior authorization process at OptumRx

When AOMs are a covered benefit, the PA flow runs through OptumRx:

1. The prescriber evaluates the patient against the OptumRx weight-management PA criteria (BMI ≥30, or ≥27 with a weight-related comorbidity, plus lifestyle-program documentation).^[8]
2. The prescriber submits the PA request through the OptumRx provider portal (or by fax on the plan's PA form). For T2D GLP-1s, the diabetes criteria set applies instead.
3. OptumRx adjudicates. Clean, well-documented requests on AOM-covered plans clear faster; complex or incompletely documented cases take longer.
4. If approved, the prescription fills at a retail pharmacy or via OptumRx mail order with the standard plan copay applied. The authorization is time-limited and continuation requires documented response.^[8]

If denied or excluded — what actually works

Ranked by cost, the practical alternatives while you appeal or if your plan permanently excludes AOMs:

• Confirm exclusion vs denial first. If it is a clinical PA denial, fix the documentation and resubmit — the cheapest fix of all. If it is a benefit exclusion, the appeal route is a dead end and you go straight to the options below.
• Pursue a covered non-weight-loss indication. If you have established cardiovascular disease plus overweight/obesity, a Wegovy PA for the CV-risk-reduction indication can succeed even on plans that exclude weight-loss use.^[7] If you have moderate-to-severe OSA (AHI ≥15), your prescriber can submit a Zepbound PA for the OSA indication rather than weight loss.^[10]
• LillyDirect Self Pay Pharmacy single-dose vials. Roughly $299/month (2.5 mg) through $699/month (10/12.5/15 mg) as of the December 2025 price reduction. Cash-pay; no insurance involvement. NovoCare offers a comparable self-pay channel for Wegovy.
• Compounded tirzepatide or semaglutide via verified 503A telehealth. Typically a few hundred dollars per month. Not brand Wegovy or Zepbound — the active ingredient is the same, but quality and supply-chain rigor vary widely. Diligence matters.
• Add an AOM rider or switch plans at open enrollment. If your plan permanently excludes AOMs, ask HR whether an anti-obesity-medication rider can be added at renewal. For provider-side cash and telehealth options, see our best semaglutide providers rankings.

Verdict — what most OptumRx members should expect

For the median member asking does OptumRx cover weight loss drugs: the answer splits cleanly by indication and by who designed the benefit.

1. T2D GLP-1s (Ozempic, Mounjaro, Trulicity, Rybelsus): generally YES on the OptumRx commercial formulary, typically Tier 2 with PA and quantity limits.
2. Chronic-weight-management GLP-1s (Wegovy, Zepbound, Saxenda): DEPENDS on whether your plan sponsor included the AOM benefit. When included, OptumRx covers them on Tier 2 with PA — and OptumRx notably kept Zepbound on its 2026 formularies when CVS Caremark dropped it. When the plan sponsor excluded AOMs, they are not covered for weight loss.
3. Wegovy cardiovascular indication: YES with PA, even on many plans that exclude weight-loss coverage, following the January 2025 Premium Formulary addition.
4. Medicare-administered plans: NO for weight-loss-only; YES for diabetes GLP-1s, the Wegovy CV indication, and the Zepbound OSA indication.

The single most important thing to understand about OptumRx specifically is that it is a PBM acting for plan sponsors — so the plan sponsor's AOM decision usually matters more than OptumRx's own clinical policy. A clean BMI and three comorbidities will not get a weight-loss GLP-1 approved on a plan that simply does not cover the drug class. Diagnose the exclusion-vs-denial question first; everything else follows. For how this looks at the insurer level, see our UnitedHealthcare, Aetna, and Kaiser Permanente coverage reviews.

Further reading

• Does UnitedHealthcare cover weight-loss drugs?
• Does Aetna cover weight-loss drugs?
• Does Kaiser Permanente cover weight-loss drugs?
• Best semaglutide providers